Our group previously published that the combination of an agonist anti-CD40 mAb together with the TLR9 activator, CpG, with or without chemotherapy could activate myeloid elements and replace M2 macrophages with M1 macrophages to induce partial anti-tumor effects in tumor bearing mice, including 9464D [25]. This evidence concerns the gene TLR9 and neoplasm.